

Product Data Sheet

VEGFR-3/FLT4 Protein, Human (Biotinylated, HEK293, His-Avi)

HY-P78872
Flt-4; FLT4; LMPH1A; PCLFLT41; VEGFR3; VEGFR-3; FLT-4; FLT-41; FLT41; PCL
Human
HEK293
P35916 (Y25-I776)
2324
115-130 kDa

PROPERTIES	
PROPERTIES	
Biological Activity	Immobilized Human VEGF-C, His Tag at 2µg/ml (100µl/Well) on the plate. Dose response curve for Biotinylated Human VEGF R3, His Tag with the EC ₅₀ of 24.3ng/ml determined by ELISA.
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 $\mu\text{g}/\text{mL}$ in ddH_2O.
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	VEGFR-2 protein is a tyrosine-protein kinase receptor that plays a crucial role in regulating various processes including angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It acts as a cell-surface receptor for VEGFA, VEGFC, and VEGFD, promoting the proliferation, survival, migration, and differentiation of endothelial cells. Additionally, isoforms lacking a transmembrane domain, such as isoform 2, act as decoy receptors for VEGFA, VEGFC, and/or VEGFD, serving as negative regulators of lymphangiogenesis by inhibiting the binding of these growth factors to FLT4. VEGFR-2 also forms heterodimers with FLT1 and FLT4, modulating their signaling. Activation of isoform 1 by vascular growth factors triggers multiple signaling cascades, including the activation of PLCG1, resulting in the production of diacylglycerol
	and inositol 1,4,5-trisphosphate, as well as the activation of protein kinase C. It also activates MAPK1/ERK2, MAPK3/ERK1, and AKT1 signaling pathways, leading to various cellular responses. Moreover, VEGFR-2 phosphorylates PIK3R1, facilitating the activation of phosphatidylinositol 3-kinase, and promotes actin cytoskeleton reorganization and activation of PTK2/FAK1. Its role in NOS2 and NOS3 induction leads to the production of nitric oxide (NO) by endothelial cells. Additionally, VEGFR-2 phosphorylates PLCG1 and promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1, and

SRC, further contributing to its diverse cellular functions.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA